86 related articles for article (PubMed ID: 11225994)
1. Immunogenetic therapy for B-cell malignancies.
Kipps TJ; Chu P; Wierda WG
Semin Oncol; 2000 Dec; 27(6 Suppl 12):104-9. PubMed ID: 11225994
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy of hematologic malignancies.
Wierda WG; Kipps TJ
Semin Oncol; 2000 Oct; 27(5):502-11. PubMed ID: 11049018
[TBL] [Abstract][Full Text] [Related]
3. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
4. CD154 gene therapy for human B-cell malignancies.
Messmer D; Kipps TJ
Ann N Y Acad Sci; 2005 Dec; 1062():51-60. PubMed ID: 16461788
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
6. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
7. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Li LH; Biagi E; Allen C; Shivakumar R; Weiss JM; Feller S; Yvon E; Fratantoni JC; Liu LN
Cancer Gene Ther; 2006 Feb; 13(2):215-24. PubMed ID: 16082377
[TBL] [Abstract][Full Text] [Related]
8. Prospects for CD40-directed experimental therapy of human cancer.
Tong AW; Stone MJ
Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
[TBL] [Abstract][Full Text] [Related]
9. Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.
Nadler LM
Semin Hematol; 1999 Oct; 36(4 Suppl 5):9-11. PubMed ID: 10528910
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells.
Tomihara K; Kato K; Masuta Y; Nakamura K; Uchida H; Sasaki K; Tanaka T; Huang J; Hiratsuka H; Hamada H
Gene Ther; 2008 Feb; 15(3):203-13. PubMed ID: 17989706
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
15. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
Batrla R; Linnebacher M; Rudy W; Stumm S; Wallwiener D; Gückel B
Cancer Res; 2002 Apr; 62(7):2052-7. PubMed ID: 11929824
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of CD23 hyperexpression on B cells from patients with rheumatoid arthritis.
De Miguel S; Galocha B; Jover JA; Bañares A; Hernández-García C; García-Asenjo JA; Fernández-Gutiérrez B
J Rheumatol; 2001 Jun; 28(6):1222-8. PubMed ID: 11409113
[TBL] [Abstract][Full Text] [Related]
17. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.
Ivanov R; Aarts T; Hagenbeek A; Hol S; Ebeling S
Cytotherapy; 2005; 7(1):62-73. PubMed ID: 16040385
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
[TBL] [Abstract][Full Text] [Related]
19. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches.
Kipps TJ
Semin Hematol; 1999 Oct; 36(4 Suppl 5):3-8. PubMed ID: 10528909
[TBL] [Abstract][Full Text] [Related]
20. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
